|
|
| | MI-3 (Menin-MLL Inhibitor) Basic information |
| Product Name: | MI-3 (Menin-MLL Inhibitor) | | Synonyms: | MI-3;Menin-MLL inhibitor 3;Thieno[2,3-d]pyriMidine, 4-[4-(4,5-dihydro-5,5-diMethyl-2-thiazolyl)-1-piperazinyl]-6-(1-Methylethyl)-;4-[4-(4,5-Dihydro-5,5-dimethyl-2-thiazolyl)-1-piperazinyl]-6-(1-methylethyl)thieno[2,3-d]pyrimidine;MI-3 (Menin-MLL Inhibitor);4-[4-(4,5-Dihydro-5,5-dimethyl-2-thiazolyl)-1-piperazinyl]-6-(1-methylethyl)thieno[2,3-d]pyrimidine MI-3;5-dihydro-5;5-dimethyl-2-thiazolyl)-1-piperazinyl]-6-(1-methylethyl) | | CAS: | 1271738-59-0 | | MF: | C18H25N5S2 | | MW: | 375.55 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1271738-59-0.mol |  |
| | MI-3 (Menin-MLL Inhibitor) Chemical Properties |
| Boiling point | 527.9±60.0 °C(Predicted) | | density | 1.36±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 8.33 mg/mL (22.18 mM; Need ultrasonic) | | form | Powder | | pka | 9.59±0.40(Predicted) |
| | MI-3 (Menin-MLL Inhibitor) Usage And Synthesis |
| Description | MI-3 is an inhibitor of the interaction between menin and mixed lineage leukemia (MLL) fusion proteins (IC50 = 648 nM). MI-3 binds to menin (Kd = 201 nM) and inhibits the menin interaction with the MLL fusion protein MLL-AF9 in HEK293 cells without affecting protein levels of menin or MLL-AF9. It inhibits growth of mouse bone marrow cells (BMCs) expressing the Hoxa9 transformation-dependent MLL fusion proteins MLL-AF9 or MLL-ENL (IC50 = 5 μM for both), as well as reduces colony formation and induces differentiation of MLL-AF9-transformed BMCs. MI-3 inhibits growth of human leukemia cell lines containing MLL translocations and decreases the expression of the transcription factors HOXA9, HOXA10, and MEIS1 in THP-1 cells. | | Uses | MI-3 (Menin-MLL Inhibitor) reverses oncogenic activity of MLL fusion proteins in leukemia. |
| | MI-3 (Menin-MLL Inhibitor) Preparation Products And Raw materials |
|